Avalo Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Avalo Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 2, 2026, with key proposals including director elections and employee stock plan approval.
NASDAQ
AVALO Therapeutics will hold its 2025 Annual Meeting on June 17, 2025, with stockholders voting on director elections, executive compensation, and auditor ratification.
NASDAQ
Avalo Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 17, 2025, to vote on director elections, executive compensation, and auditor ratification.
NASDAQ
DEFA14A: Avalo Therapeutics Sets Date for 2024 Annual Meeting, Outlines Key Proposals for Stockholder Vote
Avalo Therapeutics has scheduled its 2024 Annual Meeting for August 13, 2024, outlining several proposals for stockholder consideration, including the election of directors and approval of stock issuance.
NASDAQ
Avalo Therapeutics is holding its annual stockholder meeting on August 13, 2024, to vote on the election of directors, approval of stock issuances, equity incentive plans, and other important matters.
NASDAQ
DEFA14A: Avalo Therapeutics Acquires AlmataBio in Merger Deal, Secures $115.6 Million Private Placement
Avalo Therapeutics has acquired AlmataBio through a merger and secured a $115.6 million private placement to fund the acquisition and advance its clinical programs.